Kacie Doyle-Delgado
Family · Salt Lake City, UTNPI 1932629946
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (35.9%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 37 manufacturers reported payments, led by Dexcom, Inc. at 46.0% of the total. Among family clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 512 payments — averaging $155.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$37K
- Eli Lilly$15K
- Sanofi-aventis U.S. LLC$10K
- Insulet Corporation$5K
- Novo Nordisk$3K
- Abbott$2K
- plus $8K from 31 others
What the payments were for
- Consulting fees$16,09920%
- Speaking & faculty fees$28,57536%
- Travel & lodging$17,65022%
- Food & beverage$17,27122%
- Education$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 110 | $36,643 |
| Eli Lilly | 44 | $14,695 |
| Sanofi-aventis U.S. LLC | 51 | $9,854 |
| Insulet Corporation | 21 | $5,491 |
| Novo Nordisk | 16 | $2,534 |
| Abbott | 56 | $2,397 |
| Medtronic | 26 | $1,790 |
| Tandem Diabetes Care, Inc. | 22 | $1,652 |
| Lilly USA, LLC | 37 | $1,556 |
| Boehringer Ingelheim | 28 | $552 |
| Ascensia Diabetes Care US Inc. | 6 | $463 |
| BETA Bionics, Inc. | 10 | $336 |
| Corcept Therapeutics | 7 | $285 |
| Xeris Pharmaceuticals, Inc. | 12 | $246 |
| Merck | 13 | $195 |
| Novartis | 6 | $114 |
| Bayer | 6 | $103 |
| Sequel Med Tech, LLC | 2 | $103 |
| GSK | 6 | $93 |
| Amgen | 5 | $69 |
| Lifescan, Inc. | 4 | $59 |
| AstraZeneca | 4 | $57 |
| Paratek Pharmaceuticals, Inc. | 3 | $44 |
| Vistapharm, Inc. | 2 | $35 |
| Amarin Pharma, Inc. | 2 | $30 |
| Lucid Diagnostics Inc. | 2 | $27 |
| Esperion Therapeutics, Inc. | 1 | $23 |
| Cequr Corporation | 1 | $22 |
| AbbVie | 1 | $20 |
| Actelion Pharmaceuticals US, Inc. | 1 | $20 |
| Kyowa Kirin, Inc. | 1 | $19 |
| Amphastar Pharmaceuticals, Inc. | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Pfizer | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $14 |
| BD | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G7 GSS (161)$28,855
- DEXCOM STELO GLUCOSE BIOSENSOR$7,736
- TZIELD$5,324
- Omnipod$4,952
- DEXCOM G6 TRANSMITTER$2,790
- RYBELSUS$2,105
- t:slim X2 Insulin Pump with Control-IQ$1,071
- FREESTYLE LIBRE 3$1,030
- TOUJEO$655
- InPen$616
- iLet Bionic Pancreas$385
- Afinion 2$300
- FreeStyle Libre$261
- MINIMED 770G$199
- INPEN SMART INSULIN DELIVERY SYSTEM$164
- FreeStyle Libre Pro$135
- Ozempic$125
- Korlym$124
- FreeStyle Libre 2$120
- MINIMED 780G$115
How this compares
$79,627 in reported general payments places this provider in the 95th percentile of 1,460 family providers in Utah.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 220 | $314,360 |
| JardianceEmpagliflozin | 65 | $100,069 |
| OzempicSemaglutide | 39 | $68,340 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $64,519 |
| TrulicityDulaglutide | 44 | $60,812 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $38,281 |
| FarxigaDapagliflozin Propanediol | 32 | $38,061 |
| Tresiba Flextouch U-100Insulin Degludec | 30 | $30,218 |
| Humalog Kwikpen U-100Insulin Lispro | 34 | $19,455 |
| TradjentaLinagliptin | 13 | $15,660 |
| HumalogInsulin Lispro | 35 | $14,844 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 16 | $11,669 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 36 | $11,177 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $11,137 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 13 | $10,518 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $1,556 | $392,284318 claims |
| Boehringer IngelheimJardiance, Tradjenta | $552 | $115,72978 claims |
| Novo NordiskOzempic | $2,534 | $68,34039 claims |
| AstraZenecaFarxiga | $57 | $38,06132 claims |
| MerckJanuvia | $195 | $9,71614 claims |
| Sanofi-aventis U.S. LLCLantus | $9,854 | $3,98613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,460 family providers in Utah.
Other family in Salt Lake City
- Katrina BawdenSalt Lake City$395K
- Cortnee RomanSalt Lake City$374K
- Jared ThorleySalt Lake City$368K
- Mary SteinbackSalt Lake City$189K
- Jennalyn MayeuxSalt Lake City$151K
- Melonie ThompsonSalt Lake City$45K
- Keisa LynchSalt Lake City$39K
- Christina CardonSalt Lake City$36K
- Jessica ArbogastSalt Lake City$20K
- Jennifer LloydSalt Lake City$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.